223 related articles for article (PubMed ID: 16404595)
1. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
[TBL] [Abstract][Full Text] [Related]
2. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
[TBL] [Abstract][Full Text] [Related]
4. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
[TBL] [Abstract][Full Text] [Related]
8. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
[TBL] [Abstract][Full Text] [Related]
9. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Scheiderbauer J; Machulla HJ; Dittmann H; Vonthein R; Bares R
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):263-9. PubMed ID: 16270214
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
12. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
[TBL] [Abstract][Full Text] [Related]
15. Value of PET in the assessment of patients with neurofibromatosis type 1.
Bredella MA; Torriani M; Hornicek F; Ouellette HA; Plamer WE; Williams Z; Fischman AJ; Plotkin SR
AJR Am J Roentgenol; 2007 Oct; 189(4):928-35. PubMed ID: 17885067
[TBL] [Abstract][Full Text] [Related]
16. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
[TBL] [Abstract][Full Text] [Related]
18. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment in liposarcoma patients based on FDG PET imaging.
Brenner W; Eary JF; Hwang W; Vernon C; Conrad EU
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1290-5. PubMed ID: 16832631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]